A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors

Trial Profile

A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Erlotinib (Primary) ; Temozolomide
  • Indications Brain cancer; Germ cell and embryonal neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top